Tecan Group (TECN) investor relations material

Executive summary

• Achieved 3.4% group sales growth in local currencies in H1 2026, with both Life Sciences and Partnering segments outperforming the broader market.

• Adjusted EBITDA margin reached 15.1%, slightly ahead of last year, despite FX and tariff headwinds.

• The 'Rewired' transformation program advanced, focusing on sustainable cost savings, operational improvements, and long-term value creation.

• Outlook for full-year 2026 and medium-term 2028 targets confirmed.

• Ongoing share buyback program reduced outstanding shares, supporting EPS.

Financial highlights

• Group sales: CHF 427.5 million, up 3.4% in local currencies (down 2.7% in CHF); order entry CHF 444.3 million, up 3% in local currencies.

• Adjusted EBITDA: CHF 64.5 million (margin 15.1%), slightly above prior year.

• Adjusted net profit: CHF 32.5 million, down 3.5% year-over-year; adjusted EPS CHF 2.62, down 1.5%.

• Operating cash flow: CHF 17 million, significantly lower due to working capital changes and inventory build-up.

• Net liquidity at period-end: CHF 73.5 million.

Outlook and guidance

• Full-year 2026 guidance confirmed: low single-digit sales growth in local currencies, adjusted EBITDA margin 15.5%–16.5%.

• 2028 targets reaffirmed: CHF 1 billion in sales and 20% adjusted EBITDA margin.

• Tariff refunds of CHF 6 million expected in H2 2026, excluded from adjusted metrics.

• Beyond 2028, ambition is for mid to high single-digit sales growth and adjusted EBITDA margin above 20%.